OncoMatch

OncoMatch/Clinical Trials/NCT05592015

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Is NCT05592015 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ruxolitinib for t-cell large granular lymphocyte leukemia.

Phase 2RecruitingJonathan BrammerNCT05592015Data as of Jun 2026

Treatment: RuxolitinibThis phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

Ruxolitinib

Cancer type

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 0 prior lines

Lab requirements

Blood counts

Platelet count > 50 x 10^9/L (transfusion permitted if >50,000/uL within 5 days of last transfusion); ANC >= 100/mm^3 (G-CSF permitted if ANC remains above 100/mm^3 for 5 days after last growth-factor)

Kidney function

Serum creatinine <= 2 x ULN; eGFR >= 30 mL/min (MDRD equation); Platelets <100 x 10^9/L and renal impairment (CrCl < 90 mL/min) not permitted

Liver function

Total bilirubin <= 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted); AST and ALT <= 2.5 x ULN; ALP <= 2.5 x ULN

Platelet count > 50 x 10^9/L...Serum creatinine <= 2 x ULN...eGFR >= 30 mL/min...Total bilirubin <= 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted)...AST and ALT <= 2.5 x ULN...ALP <= 2.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Dana-Farber Cancer Institute · Boston, Massachusetts
  • Memorial Sloan Kettering Cancer Center · New York, New York
  • Ohio State University Comprehensive Cancer Center · Columbus, Ohio

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05592015 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify